デフォルト表紙
市場調査レポート
商品コード
1361745

経口固形製剤受託製造の世界市場レポート

Global Oral Solid Dosage Contract Manufacturing Market Report

出版日: | 発行: Value Market Research | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
経口固形製剤受託製造の世界市場レポート
出版日: 2023年10月01日
発行: Value Market Research
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口固形製剤受託製造市場の世界需要は、2023年~2030年の調査期間中にCAGR8.12%で成長し、2022年の329億7,000万米ドルから2030年までに615億7,000万米ドル近い市場規模に達すると予測されます。

経口固形製剤受託製造市場を牽引する主な要因には、ウイルス性疾患や慢性疾患の流行、病気を治す医薬品の増加などがあります。さらに、医薬品の広範な使用のような追加的な要因は、様々な病気に苦しむ患者のための革新的な治療法の大規模生産のための広範なニーズを引き起こしています。大手製薬企業では、大量生産の必要性が高まるにつれて、製造受託のアウトソーシングが進んでいます。その結果、革新的な医薬品の需要が高まるにつれて、経口固形製剤の受託製造のニーズも高まっています。今後数年間は、経済の繁栄と健康意識の高まりも市場成長にプラスの影響を与えると予測されます。

本調査レポートでは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を取り上げています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、経口固形製剤受託製造の世界市場における各セグメントを包括的に評価することもできます。経口固形製剤受託製造業界の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析:

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける経口固形製剤受託製造市場の現在と将来の需要を強調する地域展望をカバーします。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 経口固形製剤受託製造:産業分析

  • イントロダクション:市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 COVID-19発生の影響分析

第6章 経口固形製剤受託製造の世界市場分析:製品タイプ別

  • 概要:製品タイプ別
  • 実績データと予測データ
  • 分析:製品タイプ別
  • 錠剤
  • カプセル剤
  • 粉末
  • 顆粒剤
  • その他(トローチ、グミ、パスティルなど)

第7章 経口固形製剤受託製造の世界市場分析:メカニズム別

  • 概要:メカニズム別
  • 実績データと予測データ
  • 分析:メカニズム別
  • 即時放出
  • 遅延放出
  • 放出制御型

第8章 経口固形製剤受託製造の世界市場売上分析:エンドユーザー別

  • 概要:エンドユーザー別
  • 実績データと予測データ
  • 分析:エンドユーザー別
  • 大企業
  • 中小企業
  • その他(新興企業・ジェネリック医薬品企業)

第9章 経口固形製剤受託製造の世界市場売上分析:地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米:セグメント別
    • 北米:国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要、実績と予測
    • 欧州:セグメント別
    • 欧州:国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域の売上分析
    • 概要、実績と予測
    • アジア太平洋地域:セグメント別
    • アジア太平洋地域:国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • ラテンアメリカの売上分析
    • 概要、実績と予測
    • ラテンアメリカ:セグメント別
    • ラテンアメリカ:国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要、実績と予測
    • 中東・アフリカ:セグメント別
    • 中東・アフリカ:国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第10章 経口固形製剤受託製造企業の競合情勢

  • 経口固形製剤受託製造市場の競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第11章 企業プロファイル

  • 上位10社のシェア分析
  • 市場集中度
  • Catalent Inc
  • Lonza Group
  • Piramal Pharma Solutions
  • Aenova
  • Jubilant
  • Boehringer Ingelheim
  • AbbVie Contract Manufacturing
  • Patheon
  • Recipharm
  • Next Pharma AB
  • Siegfried AG
  • Corden Pharma
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Product Type (USD MN)
  • Tablets Market Sales by Geography (USD MN)
  • Capsules Market Sales by Geography (USD MN)
  • Powders Market Sales by Geography (USD MN)
  • Granules Market Sales by Geography (USD MN)
  • Others (Lozenges, Gummies, Pastilles, etc.) Market Sales by Geography (USD MN)
  • Analysis Market by Mechanism (USD MN)
  • Immediate-release Market Sales by Geography (USD MN)
  • Delayed-release Market Sales by Geography (USD MN)
  • Controlled-release Market Sales by Geography (USD MN)
  • Analysis by End-user (USD MN)
  • Large-size Companies Market Sales by Geography (USD MN)
  • Medium- & Small-size Companies Market Sales by Geography (USD MN)
  • Others (Startups & Generic Pharmaceutical Companies) Market Sales by Geography (USD MN)
  • Global Oral Solid Dosage Contract Manufacturing Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Oral Solid Dosage Contract Manufacturing Report
  • Market Research Process
  • Market Research Methodology
  • Global Oral Solid Dosage Contract Manufacturing Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product Type
  • Market Attractiveness Analysis by Mechanism
  • Market Attractiveness Analysis by End-user
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product Type (USD MN)
  • Tablets Market Sales by Geography (USD MN)
  • Capsules Market Sales by Geography (USD MN)
  • Powders Market Sales by Geography (USD MN)
  • Granules Market Sales by Geography (USD MN)
  • Others (Lozenges, Gummies, Pastilles, etc.) Market Sales by Geography (USD MN)
  • Global Market Analysis by Mechanism (USD MN)
  • Immediate-release Market Sales by Geography (USD MN)
  • Delayed-release Market Sales by Geography (USD MN)
  • Controlled-release Market Sales by Geography (USD MN)
  • Global Market Analysis by End-user (USD MN)
  • Large-size Companies Market Sales by Geography (USD MN)
  • Medium- & Small-size Companies Market Sales by Geography (USD MN)
  • Others (Startups & Generic Pharmaceutical Companies) Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11218732

The global demand for Oral Solid Dosage Contract Manufacturing Market is presumed to reach the market size of nearly USD 61.57 BN by 2030 from USD 32.97 BN in 2022 with a CAGR of 8.12% under the study period 2023 - 2030.

The major factors driving the oral solid dosage contract manufacturing market include the prevalence of viral and chronic diseases and increased pharmaceutical goods that can cure diseases. Moreover, additional factors like the widespread usage of pharmaceutical drugs have caused the extensive need for the large-scale production of innovative treatments for patients suffering from various ailments. Major pharmaceutical corporations are progressively outsourcing contract manufacturing as the need for large-scale production increases. As a result, as demand for innovative medicines rises, so will the need for oral solid dose contract manufacturing. In the years to come, higher economic prosperity and greater health awareness are also projected to positively impact market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of oral solid dosage contract manufacturing. The growth and trends of oral solid dosage contract manufacturing industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the oral solid dosage contract manufacturing market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

  • Tablets
  • Capsules
  • Powders
  • Granules
  • Others (Lozenges, Gummies, Pastilles, Etc.)

By Mechanism

  • Immediate-Release
  • Delayed-Release
  • Controlled-Release

By End-User

  • Large-Size Companies
  • Medium- & Small-Size Companies
  • Others (Startups & Generic Pharmaceutical Companies)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Oral Solid Dosage Contract Manufacturing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the oral solid dosage contract manufacturing market include Catalent Inc, Lonza Group, Piramal Pharma Solutions, Aenova, Jubilant, Boehringer Ingelheim, AbbVie Contract Manufacturing, Patheon, Recipharm, Next Pharma AB, Siegfried AG, Corden Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ORAL SOLID DOSAGE CONTRACT MANUFACTURING - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product Type
    • 3.7.2 Market Attractiveness Analysis By Mechanism
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET ANALYSIS BY PRODUCT TYPE

  • 6.1 Overview by Product Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Product Type
  • 6.4 Tablets Historic and Forecast Sales by Regions
  • 6.5 Capsules Historic and Forecast Sales by Regions
  • 6.6 Powders Historic and Forecast Sales by Regions
  • 6.7 Granules Historic and Forecast Sales by Regions
  • 6.8 Others (Lozenges, Gummies, Pastilles, etc.) Historic and Forecast Sales by Regions

7 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET ANALYSIS BY MECHANISM

  • 7.1 Overview by Mechanism
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Mechanism
  • 7.4 Immediate-release Historic and Forecast Sales by Regions
  • 7.5 Delayed-release Historic and Forecast Sales by Regions
  • 7.6 Controlled-release Historic and Forecast Sales by Regions

8 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY END-USER

  • 8.1 Overview by End-user
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-user
  • 8.4 Large-size Companies Historic and Forecast Sales by Regions
  • 8.5 Medium- & Small-size Companies Historic and Forecast Sales by Regions
  • 8.6 Others (Startups & Generic Pharmaceutical Companies) Historic and Forecast Sales by Regions

9 . GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE ORAL SOLID DOSAGE CONTRACT MANUFACTURING COMPANIES

  • 10.1. Oral Solid Dosage Contract Manufacturing Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF ORAL SOLID DOSAGE CONTRACT MANUFACTURING INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Catalent Inc
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Lonza Group
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Piramal Pharma Solutions
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Aenova
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Jubilant
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. Boehringer Ingelheim
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. AbbVie Contract Manufacturing
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Patheon
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Recipharm
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Next Pharma AB
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Siegfried AG
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Corden Pharma
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies